Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug half life

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    606 result(s) found for: Drug half life. Displaying page 2 of 31.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-001092-14 Sponsor Protocol Number: TIGEM5_USH Start Date*: 2023-10-12
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A phase I/II open label, dose escalation study of sub-retinal administration of a “mixture of two adeno-associated viral vectors of serotype 8 containing the 5 ´- half sequence of the human MYO7A ...
    Medical condition: Usher syndrome (USH) is characterized by the association of sensorineural hearing loss, Retinitis Pigmentosa (RP), and, in some cases, vestibular dysfunction. It is the most frequent cause of deaf-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10063396 Usher's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10063396 Usher's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003581-20 Sponsor Protocol Number: ALPHA Start Date*: 2023-03-21
    Sponsor Name:Medical University Vienna
    Full Title: Albendazole pharmacokinetics in plasma, intra-cystic fluid, and cystic tissue of human cystic and alveolar echinococcosis
    Medical condition: Albendazole is an orally administered broad-spectrum anthelmintic Drug used in treatment of human alveolar and cystic echinococcosis. To date, data on albendazole and tissue pharmacokinetics are li...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004958-34 Sponsor Protocol Number: UNOLE0457 Start Date*: 2015-01-30
    Sponsor Name:University of Leicester
    Full Title: Midazolam Measurement and Modelling using Matrix Samplers
    Medical condition: Not applicable
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003807-32 Sponsor Protocol Number: BT200-02 Start Date*: 2020-12-16
    Sponsor Name:Medical University of Vienna
    Full Title: A Phase 2a Multiple Dose “Basket Design” Study Of The Safety, Tolerability, And Pharmacologic Activity Of BT200 In Patients With Hereditary Bleeding Disorders
    Medical condition: - Patients with severe congenital hemophilia A - Patients with mild-moderate hemophilia A - Heterozygous carriers of hemophilia A - Patients with VWD Type 1, e.g. “Vicenza” type - Acquired Von Will...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001601-23 Sponsor Protocol Number: s63950 Start Date*: 2020-06-18
    Sponsor Name:University Hospitals of Leuven
    Full Title: Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long term parenteral nutrition
    Medical condition: theoretically none (PK study), but drug is used for prevention or treatment of VTE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-005240-42 Sponsor Protocol Number: CA209-686 Start Date*: 2017-05-31
    Sponsor Name:Oslo University Hospital (OUS)
    Full Title: REPORT; REirradiation and PD-1 blockade On Recurrent squamous cell head and neck Tumors
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007226-19 Sponsor Protocol Number: TZP-102-CL-G002 Start Date*: 2009-05-15
    Sponsor Name:Tranzyme Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic...
    Medical condition: The medical condition to be investigated is gastroparesis due to diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002466-13 Sponsor Protocol Number: NICITA Start Date*: 2019-10-23
    Sponsor Name: Institut für Klinische Krebsforschung IKF GmbH
    Full Title: Nivolumab with chemotherapy in pleural mesothelioma after surgery
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001357-17 Sponsor Protocol Number: CONTINUATION-PV Start Date*: 2014-11-03
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici...
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) PL (Completed) SK (Completed) BG (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001480-23 Sponsor Protocol Number: IMMUNIB Start Date*: 2019-02-22
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: IMMUNIB - An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC)
    Medical condition: advanced stage hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077738 Hepatocellular carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000666-10 Sponsor Protocol Number: m16-063 Start Date*: 2018-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subje...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002471-25 Sponsor Protocol Number: BN40697(ISIS443139-CS2) Start Date*: 2018-10-18
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVES...
    Medical condition: Early Manifest Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002485-70 Sponsor Protocol Number: CA008-002 Start Date*: 2016-07-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-003934-33 Sponsor Protocol Number: FIL_BRidge Start Date*: 2014-09-10
    Sponsor Name:Fondazione Italiana Linfomi Onlus
    Full Title: A pilot phase II study with BRENTUXIMAB VEDOTIN as pre-ASCT induction therapy in relapsed/refractory Hodgkin’s lymphoma patients non responding to IGEV salvage treatment.
    Medical condition: Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000192-20 Sponsor Protocol Number: PL3397-A-U4003 Start Date*: 2020-07-22
    Sponsor Name:DAIICHI SANKYO, INC.
    Full Title: A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
    Medical condition: Tenosynovial giant cell tumor (TGCT) is a group of neoplasms including pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062856 Giant cell tumour of tendon sheath benign LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000201-69 Sponsor Protocol Number: D5290C00005 Start Date*: 2019-08-13
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-...
    Medical condition: The prevention of medically attended RSV LRTI.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) LV (Completed) GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) BG (Completed) CZ (Completed) EE (Completed) HU (Completed) LT (Completed) PL (Completed) FI (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001172-21 Sponsor Protocol Number: CLO05908 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Japan K.K.
    Full Title: A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000072-17 Sponsor Protocol Number: BH30071 Start Date*: 2016-06-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH...
    Medical condition: Haemophilia A without factor VIII inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing) DE (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010719-33 Sponsor Protocol Number: Gebro-III-48-4 Start Date*: 2009-05-27
    Sponsor Name:Gebro Pharma GmbH
    Full Title: Prospective, clinical trial to investigate safety, tolerability and efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension (test) compared to Ibuprofen 400 mg powder for oral suspension (...
    Medical condition: Osteoarthritis of the hip or knee
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 18:23:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA